Zolpidem in Progressive Supranuclear Palsy

Abstract EN

Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disorder, characterized by motor symptoms, postural instability, personality changes, and cognitive impairment.

There is no effective treatment for this disorder.

Reduced neurotransmission of GABA in the striatum and globus pallidus may contribute to the symptoms of motor and cognitive symptoms seen in PSP.

Zolpidem is a GABA agonist of the benzodiazepine subreceptor BZ1.

Here a nondiabetic, normotensive case of PSP is (Progressive Supranuclear Palsy) described, which showed improvement in swallowing, speech, and gaze paresis after zolpidem therapy and possible mechanism of actions are discussed.

However, more trials are needed with large number of patients to confirm the effectiveness of zolpidem in progressive supranuclear palsy.